Exjade is a Oral Tablet, For Suspension in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Deferasirox.
| Product ID | 0078-0470_12e80115-bfb7-4292-89cc-e696a3c6c325 |
| NDC | 0078-0470 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Exjade |
| Generic Name | Deferasirox |
| Dosage Form | Tablet, For Suspension |
| Route of Administration | ORAL |
| Marketing Start Date | 2005-11-30 |
| Marketing Category | NDA / NDA |
| Application Number | NDA021882 |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Substance Name | DEFERASIROX |
| Active Ingredient Strength | 500 mg/1 |
| Pharm Classes | Iron Chelating Activity [MoA],Iron Chelator [EPC],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2005-11-30 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA021882 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2005-11-30 |
| Ingredient | Strength |
|---|---|
| DEFERASIROX | 500 mg/1 |
| SPL SET ID: | 3495a70c-870c-4968-940e-8baea152cf85 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0078-0468 | Exjade | deferasirox |
| 0078-0469 | Exjade | deferasirox |
| 0078-0470 | Exjade | deferasirox |
| 0078-0654 | Jadenu | deferasirox |
| 0078-0655 | Jadenu | deferasirox |
| 0078-0656 | Jadenu | deferasirox |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() EXJADE 88575851 not registered Live/Pending |
QINGDAO YUZHUO COSMETIC PRODUCTS CO., LTD 2019-08-12 |
![]() EXJADE 78304307 2875038 Live/Registered |
NOVARTIS AG 2003-09-23 |
![]() EXJADE 78089460 2773531 Dead/Cancelled |
Novartis AG 2001-10-22 |